{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:39:23Z","timestamp":1791434363973,"version":"4.3.3"},"reference-count":35,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Corporal Michael J. Crescenz Veterans Affairs Medical Center"},{"name":"Robert Wood Johnson Foundation Clinical Scholars Program"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Substance Abuse"],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Syringe exchange programs are uniquely positioned to offer treatment services to interested clients. Prevention Point Philadelphia recently expanded to offer buprenorphine maintenance treatment through its Stabilization, Treatment, and Engagement Program (STEP).\n                      <jats:italic toggle=\"yes\">Objective:<\/jats:italic>\n                      To describe the STEP model of care and report treatment outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec sec-type=\"methods\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective chart review of patients enrolled in STEP (October 2011-August 2014). Our main outcome measure was time retained in treatment, defined as time from treatment initiation to treatment failure. Secondary outcome measures were buprenorphine and opiate use, from urine toxicology screens. We analyzed retention in treatment using Kaplan-Meier survival estimates; patients who remained in treatment at the end of the study period were censored on that day. For buprenorphine and opiate use, we calculated the percentage of patients who were positive for buprenorphine and opiates in each month of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec sec-type=\"results\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 124 patients enrolled in STEP, the median age was 41 (range 21 to 63) and 80% reported injection heroin use. Comorbidities were common: 33% had HIV infection, most reported anxiety (78%) or depression (71%), and 20% were homeless. The most common program outcomes were unplanned self-discharge (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 29; 23%), incarceration (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 20; 16%), and administrative discharge (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 19; 15%). The percentage of patients retained in treatment at 3, 6, 9, and 12 months was 77%, 65%, 59%, and 56%, respectively. Among those retained, the percentage with a positive buprenorphine screen at 3, 6, 9, and 12 months was 88%, 100%, 96%, and 95%, respectively. The percentage with a positive opiates screen was 19%, 13%, 17%, and 16%, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec sec-type=\"conclusions\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>With a program that blended organizational and community resources, retention in buprenorphine maintenance treatment was comparable to retention rates reported from other settings. Further research should directly compare treatment outcomes in syringe exchange program-based settings versus primary care and specialty settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1080\/08897077.2018.1443541","type":"journal-article","created":{"date-parts":[[2018,2,23]],"date-time":"2018-02-23T15:33:34Z","timestamp":1519400014000},"page":"167-172","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":64,"title":["Description and Outcomes of A Buprenorphine Maintenance Treatment Program Integrated within Prevention Point Philadelphia, An Urban Syringe Exchange Program"],"prefix":"10.1177","volume":"39","author":[{"given":"Marcus A.","family":"Bachhuber","sequence":"first","affiliation":[{"name":"Division of General Internal Medicine, Department of Medicine, Montefiore Medical Center\/Albert Einstein College of Medicine, Bronx, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cole","family":"Thompson","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Prybylowski","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Benitez","sequence":"additional","affiliation":[{"name":"Prevention Point Philadelphia, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Mazzella","sequence":"additional","affiliation":[{"name":"Prevention Point Philadelphia, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Barclay","sequence":"additional","affiliation":[{"name":"Prevention Point Philadelphia, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2018,4,1]]},"reference":[{"key":"e_1_3_3_2_1","volume-title":"Key substance use and mental health indicators in the United States: Results from the 2015 National Survey on Drug Use and Health (HHS Publication No. SMA 16\u20134984, NSDUH Series H-51)","author":"Center for Behavioral Health Statistics and Quality","year":"2016","unstructured":"Center for Behavioral Health Statistics and Quality. Key substance use and mental health indicators in the United States: Results from the 2015 National Survey on Drug Use and Health (HHS Publication No. SMA 16\u20134984, NSDUH Series H-51). Rockville, MD 2016."},{"issue":"273","key":"e_1_3_3_3_1","first-page":"1","article-title":"Drug Overdose Deaths in the United States, 1999\u20132015","author":"Hedegaard H","year":"2017","unstructured":"Hedegaard H, Warner M, Minino AM. Drug Overdose Deaths in the United States, 1999\u20132015. NCHS Data Brief. 2017(273):1\u20138.","journal-title":"NCHS Data Brief"},{"issue":"1","key":"e_1_3_3_4_1","first-page":"1","article-title":"Overdose deaths involving opioids in Philadelphia","volume":"1","author":"Philadelphia Department of Public Health","year":"2016","unstructured":"Philadelphia Department of Public Health. Overdose deaths involving opioids in Philadelphia. CHART. 2016;1(1):1\u20138.","journal-title":"CHART"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2010.05.004"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2015.302664"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.5055\/jom.2013.0152"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2013.09.003"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.5055\/jom.2010.0034"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2015.1011820"},{"key":"e_1_3_3_11_1","volume-title":"Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction (Treatment Improvement Protocol (TIP) Series, No. 40.)","year":"2004","unstructured":"Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction (Treatment Improvement Protocol (TIP) Series, No. 40.). Rockville, MD 2004."},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1521-0391.2013.12032.x"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2016.10.039"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-006-0023-1"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2011.620475"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-010-1306-0"},{"key":"e_1_3_3_17_1","first-page":"1","article-title":"Recent incarceration and buprenorphine maintenance treatment outcomes among human immunodeficiency virus-positive patients","author":"Riggins DP","year":"2016","unstructured":"Riggins DP, Cunningham CO, Ning Y, Fox AD. Recent incarceration and buprenorphine maintenance treatment outcomes among human immunodeficiency virus-positive patients. Subst Abus. 2016:1\u20136.","journal-title":"Subst Abus"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2010.12.002"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-008-0866-8"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2010.01.001"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2016.12.010"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/10550887.2012.694603"},{"issue":"7","key":"e_1_3_3_23_1","first-page":"500","article-title":"Buprenorphine treatment in an urban community health center: what to expect","volume":"40","author":"Cunningham C","year":"2008","unstructured":"Cunningham C, Giovanniello A, Sacajiu G, . Buprenorphine treatment in an urban community health center: what to expect. Fam Med. 2008;40(7):500\u2013506.","journal-title":"Fam Med"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1353\/hpu.2014.0139"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.5055\/jom.2014.0204"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000071"},{"key":"e_1_3_3_27_1","article-title":"Buprenorphine Outpatient Outcomes Project: can Suboxone be a viable outpatient option for heroin addiction","volume":"4","author":"Sittambalam CD","year":"2014","unstructured":"Sittambalam CD, Vij R, Ferguson RP. Buprenorphine Outpatient Outcomes Project: can Suboxone be a viable outpatient option for heroin addiction? J Community Hosp Intern Med Perspect. 2014;4.","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2013.07.007"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2012.12.008"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2011.587704"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.541"},{"key":"e_1_3_3_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000000727"},{"key":"e_1_3_3_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.12553"},{"key":"e_1_3_3_34_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-017-0072-2"},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0b013e31829727b2"},{"key":"e_1_3_3_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2015.04.010"}],"container-title":["Substance Abuse"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1080\/08897077.2018.1443541","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1080\/08897077.2018.1443541","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1080\/08897077.2018.1443541","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:49:47Z","timestamp":1777625387000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1080\/08897077.2018.1443541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.1080\/08897077.2018.1443541"],"URL":"https:\/\/doi.org\/10.1080\/08897077.2018.1443541","relation":{},"ISSN":["0889-7077","1547-0164"],"issn-type":[{"value":"0889-7077","type":"print"},{"value":"1547-0164","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4]]}}}